Inmagene Completes Enrollment for its Phase 2a Trial of IMG-007 for Alopecia Areata

Inmagene Biopharmaceuticals has finalized patient enrollment for its Phase 2a clinical trial of IMG-007, a nondepleting anti-OX40 monoclonal antibody, in adult patients with alopecia areata (AA). The trial will assess IMG-007’s safety and efficacy, using the severity of alopecia tool (SALT) score in patients with over 50% scalp hair loss. With an enrollment of 29 patients across 11 sites in the U.S. and Canada, the study will evaluate the impact of three infusions over four weeks, with a follow-up period of 24 weeks. Topline results for this study are expected in Q4 2024, which will guide further understanding of the drug’s potential in treating AA.